{"entity":{"id":"nct07529782","kind":"trial","name":"Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1 trial of Pamlectabart tismanitin run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.","summary":"Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07529782 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 15 participants planned, started 2026-03-17. Conditions recorded: Multiple Myeloma and Other Plasma Cell Neoplasms. Interventions recorded: HDP-101.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07529782","url":"https://clinicaltrials.gov/study/NCT07529782"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["pamlectabart-tismanitin"],"companies":["heidelberg-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07529782","phase":"1","setting":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Chinese Patients With Plasma Cell Disorders Including Multiple Myeloma","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07529782/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"pamlectabart-tismanitin","kind":"drug","name":"Pamlectabart tismanitin","route":"/drugs/pamlectabart-tismanitin/"}],"company":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/"}]}}